Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Status:
Completed
Trial end date:
2016-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether the investigational drug GM602, is
effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot
blocking the flow of blood through one, or more of the blood vessels supplying the brain)
when administered up to 18 hours after symptoms begin.
Phase:
Phase 2
Details
Lead Sponsor:
Genervon Biopharmaceuticals, LLC
Collaborators:
California Pacific Medical Center Research Institute Columbia University Hoag Memorial Hospital Presbyterian Huntington Hospital Sarasota Memorial Hospital University Hospital Erlangen University of California, Los Angeles University of Louisville